Adage Capital Partners GP L.L.C. Sells 2,421,899 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Adage Capital Partners GP L.L.C. decreased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 66.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,200,000 shares of the company's stock after selling 2,421,899 shares during the quarter. Adage Capital Partners GP L.L.C. owned 0.11% of Teva Pharmaceutical Industries worth $26,448,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in TEVA. Barclays PLC grew its holdings in shares of Teva Pharmaceutical Industries by 31.7% in the 3rd quarter. Barclays PLC now owns 427,595 shares of the company's stock worth $7,705,000 after purchasing an additional 102,848 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Teva Pharmaceutical Industries in the third quarter worth about $50,000. Franklin Resources Inc. lifted its position in shares of Teva Pharmaceutical Industries by 141.7% during the third quarter. Franklin Resources Inc. now owns 155,091 shares of the company's stock worth $2,674,000 after purchasing an additional 90,920 shares in the last quarter. DGS Capital Management LLC lifted its position in shares of Teva Pharmaceutical Industries by 6.8% during the third quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock worth $246,000 after purchasing an additional 872 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Teva Pharmaceutical Industries by 44.5% in the fourth quarter. GAMMA Investing LLC now owns 7,458 shares of the company's stock valued at $164,000 after purchasing an additional 2,297 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Trading Up 0.4 %

Shares of TEVA stock traded up $0.06 during trading hours on Thursday, reaching $15.57. The company had a trading volume of 4,681,095 shares, compared to its average volume of 9,933,264. The company has a 50 day moving average of $15.13 and a 200 day moving average of $17.52. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The firm has a market cap of $17.65 billion, a price-to-earnings ratio of -10.75, a P/E/G ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Bank of America dropped their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. Barclays dropped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday, April 23rd. Finally, Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.